Physician profile
Carmel R Boykin-Wright
NPI 1487724381
$2,746.46
in general payments reported to CMS, 2019-2025
18 companies · $31.75 in 2025
The $31.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $201 · 2021: $613 · 2022: $525 · 2023: $389 · 2025: $31.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.42 | 2019-2022 | |
| Pfizer INC. | $435.10 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $249.57 | 2019-2020 | |
| Astellas Pharma US INC | $246.42 | 2019-2021 | |
| Lilly USA, LLC | $185.67 | 2019-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $133.46 | 2022-2023 | Rexulti |
| Medtronic, INC. | $116.34 | 2022-2023 | Vanta Adaptivestim |
| Novo Nordisk INC | $106.95 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.93 | 2019-2022 | |
| Sanofi Pasteur INC. | $80.68 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $71.03 | 2019-2022 | |
| Mylan Specialty L.P. | $67.61 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $60.09 | 2020-2023 | Fasenra |
| Exact Sciences Corporation | $52.81 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $44.31 | 2023-2025 | Shingrix, Arexvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $17.93 | 2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Gilead Sciences, INC. | $16.09 | 2019 | |
| Bioventus LLC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmel Boykin-Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.